Evidence map›Paper›PMID 40148297›Full record

ArticleCurrent pharmaceutical design2026

Treatment with

Mehrdad Moetamani-Ahmadi, Seyedeh Elnaz Nazari, Fereshteh Asgharzadeh, Nima Zafari, Mahla Velayati, Hamed Akbarzade, Maryam Alaei, Zhara Negahbanzaferanloo, Elmira Lagzian, Ibrahim Saeed Gataa and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mehrdad Moetamani-AhmadiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyedeh Elnaz NazariMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Fereshteh AsgharzadehMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Nima ZafariMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahla VelayatiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hamed AkbarzadeDepartment of Medical Genetics, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam AlaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Zhara NegahbanzaferanlooMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Elmira LagzianDepartment of Medical Genetics, Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ibrahim Saeed GataaDepartment of Medicine, College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsDepartment of Medical Chemistry, Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, United Kingdom.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

Mashhad University of Medical Sciences 962782AA
6 · The paper itself

Abstract

objectiveDespite recent advances in surgical procedures, postoperative peritoneal adhesions are common following major abdominopelvic surgery. Here, the therapeutic potential of Punica granatum var. pleniflora (PGP) on postoperative peritoneal adhesions has been explored in a rat uterine horn adhesion model.

methodsEighteen Albino Wistar female rats were divided into three groups: control group, sham, and treatment group receiving 400 mg/kg/day PGP orally for ten days. An identical surgical technique was employed to induce adhesion of the uterine horn in both the control and treatment groups. At the end of the experiments, all rats were re-operated for evaluation of adhesion. The macroscopic evaluation and fibrotic bands scaling were conducted and inflammation and fibrosis were assessed and graded, microscopically. Additionally, the effect of PGP on inflammation and fibrosis was assessed via PCR, ELISA, and histopathology.

resultsPGP could significantly reduce the peritoneal adhesion score (treatment group vs. control group; p<0.001). Histopathological analysis indicated that PGP prevented adhesion formation by suppressing inflammation and fibrosis. Moreover, inflammatory and fibrosis biomarkers were decreased following PGP treatment. Furthermore, rats in the treatment group had significantly lower oxidative stress markers in adhesion tissues when compared to the control group.

conclusionOral PGP was associated with reduced peritoneal adhesion formation in rats, postoperatively. This therapy might be an effective and safe strategy for preventing intraperitoneal adhesion after abdominopelvic surgeries.

Indexed as

Disease Models, AnimalPlant ExtractsPomegranatePostoperative ComplicationsUterusAnimalsFemaleInflammationRatsRats, WistarTissue AdhesionsPlant Extractsabdominopelvic surgeries.fibrosisinflammationmesothelial cellspostoperative peritoneal adhesionPunica granatum var. pleniflora

Identifiers

PMID40148297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.